Currently, passive immunotherapies, based on mAbs targeting different cellular checkpoint controllers, had changed the landscape of cancer treatment, such as those blocking cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and programmed cell death 1 (PD-1) or its ligand PD-L1 (42). This evidence concerns the gene PDCD1 and cancer.